Overexpression of TNF contributes to pathogenesis of multiple autoimmune diseases, accounting for a remarkable success of anti-TNF therapy. TNF is produced by a variety of cell types, and it can play either a beneficial or a deleterious role. In particular, in autoimmunity pathogenic TNF may be derived from restricted cellular sources. In this study we evaluated the feasibility of cell-type-restricted TNF inhibition in vivo. To this end, we engineered MYSTI (Myeloid-Specific TNF Inhibitor)-a recombinant bispecific antibody that binds to the F4/80 surface molecule on myeloid cells and to human TNF (hTNF). In macrophage cultures derived from TNF humanized mice MYSTI could capture the secreted hTNF, limiting its bioavailability. Additionally, as evaluated in TNF humanized mice, MYSTI was superior to an otherwise analogous systemic TNF inhibitor in protecting mice from lethal LPS/D-Galactosamine-induced hepatotoxicity. Our results suggest a novel and more specific approach to inhibiting TNF in pathologies primarily driven by macrophage-derived TNF.
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anti-cytokine therapy | TNF | bispecific antibody | autoimmunity | humanized mice T NF is a proinflammatory and immunoregulatory cytokine with diverse functions in host defense and in immune homeostasis. When overexpressed systemically or in distinct histological compartments, TNF may contribute to various disease states. In particular, TNF has long been known as one of the key cytokines involved in the development of rheumatoid arthritis (1), ankylosing spondylitis (2), Crohn's disease (3), multiple sclerosis (4), psoriasis (5) , and several other autoimmune diseases (6, 7) . Disrupting TNF signaling by recombinant monoclonal antibodies or engineered soluble receptors proved to be effective in patients and became an important therapeutic option in treatment of some of these conditions (8) (9) (10) (11) , whereas in other cases it was found to be ineffective (12) or even detrimental (13) . Importantly, systemic TNF inhibition may itself cause autoimmune conditions (14) , disrupt organized lymphoid microstructure (15) , and induce severe side effects, such as reactivation of latent tuberculosis infection (16) , suggesting a potential divergent nature of TNF-mediated signaling.
Among the cell types capable of producing TNF are macrophages, monocytes, neutrophils, dendritic cells, T and B lymphocytes, and several types of stromal cells (17) . We have previously reported that cellular sources of TNF specify its distinct functions in protective and autoreactive immune responses (18, 19) and in controlling of secondary lymphoid organ microstructure (20) . TNF derived from myeloid cells was shown to play a nonredundant deleterious role in several disease models. TNF is a transmembrane protein, which needs to be cleaved off to act systemically. The complex multilevel regulation of ADAM17 metalloprotease activity, which cleaves the transmembrane TNF (21, 22) , suggests that different cell types may vary in the efficiency of TNF precursor processing.
Monocytes and macrophages play a very prominent role in autoimmunity, in particular, in rheumatoid arthritis (23) , and they are among the main cellular sources of TNF (18) . As macrophages are also the primary source of systemic pathogenic TNF in the models of severe sepsis and (alongside T-cell-derived TNF) in concanavalin-A-induced hepatitis (18) and experimental autoimmune encephalomyelitis (EAE) (19) , we hypothesized that it may be advantageous to selectively target macrophage-derived TNF. One of the approaches to achieve this goal would be to use a bispecific reagent that binds to a membrane-associated molecule expressed selectively on monocytes/macrophages and simultaneously binds (and neutralizes) TNF secreted by the targeted cell.
F4/80 is a cell-surface molecule highly expressed on murine monocytes and tissue macrophages (including Kupffer cells in the liver) and is widely used as a specific lineage marker in flow cytometry and immunohistology (24, 25) .
To address the hypothesis that cell-type-restricted TNF inhibition can be advantageous in certain disease models, we have constructed bispecific antibodies designated here as Myeloid-Specific TNF Significance Anti-cytokine therapy has revolutionized the treatment of autoimmune diseases. However, recent data suggest that cytokines, in particular TNF, produced by various cell types may play distinct and sometimes opposite roles in the inflammatory responses. In certain autoimmune diseases TNF produced by monocytes and macrophages plays a pathogenic role, whereas TNF produced by T cells may be protective. In addition, T-cell-derived TNF is indispensable for resistance to infections, such as tuberculosis. To demonstrate that cell-type-restricted anti-cytokine therapy may be advantageous, we generated bispecific antibodies that neutralize TNF produced by myeloid cells. Cell-targeted inhibition of TNF is more effective than systemic TNF ablation in protecting mice from TNF-mediated hepatotoxicity. This provides a rationale for the development of novel anti-TNF agents. This article is a PNAS Direct Submission.
Data deposition: The sequences reported in this paper have been deposited in the GenBank database (accession nos. KU677977, KU677978, KU695528, and KU695529). Inhibitors (MYSTI), which simultaneously bind F4/80 and human TNF (hTNF) and inhibit interaction of TNF with its receptors (Fig. 1A) , as well as similar control antibodies referred to as Systemic TNF Inhibitors (STI) unable to bind F4/80 but with preserved hTNF binding.
We demonstrated that in vitro MYSTI, but not STI, could attach to the cell surface of macrophages and prevent TNF secretion into the culture media. Most importantly, in vivo at the same dose MYSTI was superior to its nontargeted counterpart (STI) in protecting mice from lethal LPS/D-Galactosamine (D-Gal) toxicity, an experimental model in which myeloid cells are the principal source of deleterious TNF (18) . This study provides a rationale for cell-type-restricted anti-cytokine therapy.
Results
Cloning, Expression, and Purification of MYSTI and STI Recombinant Antibodies. We have designed two bispecific antibodies comprising anti-F4/80 and anti-hTNF domains that bind and neutralize human TNF secreted by monocytes and macrophages derived from TNF humanized mice (26) . For both antibodies we have created appropriate controls serving as systemic TNF inhibitors (Fig. 1B) .
MYSTI-1 antibody comprised anti-F4/80 single-chain antibody (scFv) and a previously reported high-affinity single-domain antibody (V H H) targeting human TNF (27) (28) (29) joined by a flexible glycine-serine linker. A C-terminal histidine tag was genetically added to facilitate its purification. To create appropriate control antibody STI-1, we used the intact anti-TNF moiety of MYSTI-1, but substituted the cDNA coding for anti-F4/80 scFv with a denovo-synthesized scFv gene in which all six complementarity determining regions (CDRs) were replaced with (Gly 4 Ser) n sequences of the same length.
MYSTI-2 antibody comprised a novel anti-F4/80 V H H ( Fig. S1 ; Fig. S2 , Table S1 ; SI Materials and Methods) and the same anti-TNF V H H module as in MYSTI-1/STI-1, whereas its control-STI-2-contained an irrelevant V H H (30) in place of anti-F4/80 moiety, thus acting as a systemic TNF inhibitor. All recombinant antibodies were expressed in Escherichia coli and purified by affinity chromatography (for SDS/PAGE, see Fig. S3 ).
Binding of MYSTI and STI to Recombinant Human TNF and Inhibition of Its Activity. Kinetics of interactions of bispecific antibodies with recombinant hTNF was determined by surface plasmon resonance (SPR). All recombinant antibodies demonstrated high-affinity interaction with hTNF and had similar on-and off-rates ( Fig. 1 D and E and Table S2 ). The low dissociation rate of the MYSTI antibodies suggested that they may be capable of remaining bound to the hTNF.
To compare TNF-inhibitory properties of MYSTI and STI, we performed a TNF-induced cytotoxicity assay using the L929 murine fibrosarcoma line and found that MYSTI and STI had very similar hTNF inhibitory activity in vitro (Fig. 1C) .
MYSTI but Not STI Binds to the Surface of Macrophages via Anti-F4/80
Moiety. Flow cytometry analysis demonstrated that bispecific antibody MYSTI via interaction with the F4/80 protein could attach to both peritoneal cavity macrophages ( Fig. 2 A and B and Fig. S4 A and B) and bone-marrow-derived macrophages (Fig. 2G) , whereas mutations or substitutions introduced into STI prevented binding to F4/80 (Fig. 2H) . Lack of MYSTI interaction with F4/80 negative cells (mostly B and T cells) (Fig. 2C and Fig. S4C ) and observed decrease in F4/80 counterstaining in samples preincubated with MYSTI ( Fig. 2D and Fig. S4D ) confirmed a specific interaction with F4/80. Importantly, we also demonstrated that MYSTI could bind macrophage-associated F4/80 and hTNF simultaneously (Fig. 2 E and F and Fig. S5 ). Thus, these bispecific reagents can selectively capture hTNF produced by macrophages.
Retention of Endogenously Produced hTNF on the Surface of Macrophages by MYSTI. As the anti-TNF moiety of both MYSTI and STI could bind and neutralize human but not murine TNF (27) , in all subsequent experiments we used primary cells derived from TNF humanized mice in which the murine TNF gene was substituted by its human counterpart (26, 31, 32) . Peritoneal cavity macrophages from such mice were used to test whether MYSTI could prevent the release of soluble hTNF into the culture medium upon LPS stimulation. We found that hTNF levels in the supernatants of macrophage cultures were significantly reduced when macrophages were preincubated with MYSTI and then washed, suggesting that soluble hTNF released by macrophages was captured and retained by bispecific antibody on the surface of the peritoneal cavity macrophages at least for the duration of the experiment (Fig. 3A) . These findings were confirmed with bonemarrow-derived macrophage cultures from TNF humanized mice: preincubation with MYSTI significantly decreased hTNF activity in supernatants upon LPS stimulation, whereas preincubation with neutralizing but monospecific anti-TNF V H H or with STI did not (Fig. 3 B and C) . Interestingly, MYSTI can be internalized from the macrophage membrane (Fig. S7) .
Advantage of Macrophage-Targeted Versus Systemic TNF Inhibition in LPS/D-Galactosamine-Induced Hepatotoxicity. We established previously that macrophages are the source of deleterious TNF in LPS/D-Gal-induced hepatotoxicity (18) . We also found that this toxicity can be inhibited by administration of anti-hTNF antibodies or soluble TNF receptors in TNF humanized mice (32) . To compare the effects of macrophage/monocyte targeted TNF retention (represented by MYSTI) as opposed to systemic TNF inhibition (represented by STI), we compared these two pairs of recombinant antibodies in the experimental model of acute hepatotoxicity in TNF humanized mice. MYSTI-1 and STI-1 at doses of 750 U/g or the vehicle buffer were injected 30 min before LPS/D-Gal administration. All of the mice that received MYSTI-1 survived (Fig. 4A) whereas a similar dose of STI-1 antibody, which had otherwise the same anti-TNF activity and similar molecular weight (MW) and pI, was insufficient to protect mice from lethality, although at higher doses STI also prevented the hepatotoxicity (Fig. S8) .
The superior efficiency of macrophage-targeted anti-TNF therapy was reproduced in a comparison of independently developed macrophage-specific TNF inhibitor MYSTI-2 with its respective control antibody STI-2 (Fig. 4B) . This result is consistent with significantly lower levels of hTNF in sera of TNF humanized mice stimulated with LPS after MYSTI-2 administration compared with STI, despite the fact that both reagents carried an identical hTNF-binding V H H module (Fig. 4C) . MYSTI but not STI was able to bind to F4/80-positive peritoneal macrophages in vivo (Fig. 4D) , thereby preventing LPS-mediated TNF production (Fig. S9) .
Overall these results suggested that macrophage-targeted inhibition of TNF is advantageous in terms of required drug dose for protection/survival.
Discussion
Anti-TNF therapy is currently widely used for multiple autoimmune disorders. However, due to intrinsic nonredundant beneficial functions of TNF, its inhibition is associated with several side effects, such as increased susceptibility to infections (33) , secondary autoimmune manifestations (34, 35) , and potentially increased risk of lymphoma development (36) . Therefore, there is an interest in the development of anti-TNF agents, which would be able to discriminate between mainly pathogenic TNF and "physiological" TNF required for immune homeostasis as more selective reagents may result in fewer side effects.
The apparent nonredundancy of TNF produced by various cellular subsets could be attributed to kinetics, level of the expression, and/or compartmentalization of TNF-producing cells during a particular disease state. Kinetics and the level of expression by various cell types is induced by a variety of stimuli and controlled by distinct intracellular cascades that may differ in specific cell types. For example, macrophages can rapidly produce large TNF quantities upon triggering of Toll-like receptors (TLRs), whereas T cells require other stimuli, such as T-cell receptor engagement, and may produce TNF with different kinetics (37, 38) .
Additionally, TNF is initially synthesized by all cells as a type II transmembrane protein that is subsequently cleaved by metalloprotease ADAM17 (TACE) to generate the soluble form of the cytokine. Thus, one of the explanations for the potential difference in the functions of TNF produced by myeloid cells versus T cells could be related to the molecular form of TNF (membrane bound vs. soluble) as their relative levels may differ in these cell types. Obviously, membrane-bound TNF cannot enter the circulation and produce the massive systemic effects observed in several experimental models, including LPS/D-Gal challenge. Indeed, mice producing only membrane-bound TNF are protected from this type of lethal toxicity (39, 40) . We have previously provided evidence for the significance of both the cellular source and the molecular form of TNF in the maintenance of the microstructure of lymphoid tissues (20) . Thus, cell-type-restricted TNF blockade may selectively disrupt certain signaling circuits deleterious for the host, but not necessarily neutralize the entire "homeostatic" or protective TNF signaling.
Myeloid cells are critical players in many autoimmune diseases, found in large quantities at the effector sites, and one of the major producers of TNF in the body. Taking this into account, a possible improvement of existing anti-TNF therapeutic options by selective inhibition of TNF produced by macrophages appears reasonable. A recent study demonstrated that for the resistance to Mycobacterium tuberculosis infection in mice T-cell-derived TNF appears critical and nonredundant for immune protection (41) . This is consistent with the mode of protection through the formation of bactericidal granulomas whose structural integrity depends on TNF produced by T cells, presumably in membrane-bound form (41, 42) . In both humans and mice, systemic anti-TNF treatment is known to affect granuloma integrity and may cause reactivation of latent disease (43) .
The strategy developed in our study employs targeting TNFneutralizing antibody to the macrophage surface via interaction with membrane protein F4/80. Binding to the surface molecule could induce internalization of antibody and/or induce intracellular signaling events via F4/80. Potentially, such antibody may also bind transmembrane TNF on the surface of macrophages and thus mediate an anti-inflammatory effect by the mechanism of reverse TNF signaling (44) . Regardless of the mechanism, our in vivo and in vitro experiments indicate that binding of antibody per se does not activate macrophages as determined by TNF production. However, in primary macrophages prepared from TNF humanized mice, MYSTI (but not STI) can bind and retain TNF on the surface of macrophages, preventing its bioavailability. In vivo administration of MYSTI before LPS challenge resulted in a dramatic reduction in LPS-induced hTNF serum levels in humanized mice with STI having appreciably smaller effect. Interestingly, MYSTI administration blocked very early TNF production by peritoneal macrophages (Fig. S9) . Most importantly, MYSTI can block in vivo TNF activity during acute septic shock more efficiently than the control antibody representing a systemic TNF inhibitor.
Altogether, we propose a novel anti-cytokine therapeutic strategy based on selective inhibition of a cytokine from restricted cellular subsets known to be the main source of pathogenic activity in disease. In the future it will be interesting to assess the efficacy of such reagents (perhaps targeting other proinflammatory cytokines) in relevant chronic disease models, such as experimental arthritis, colitis, and EAE. 
Materials and Methods
Mice. As recombinant hTNF inhibitors with the sole exception of Etanercept do not bind murine TNF with sufficient affinity to block its biological effects, we have generated human TNF knock-in mice here designated as TNF humanized mice (31) . In these mice, lacking murine TNF, human TNF mediates protective and pathogenic functions and could be neutralized with the entire panel of available anti-TNF drugs. hTNF KI mice were bred at the Animal Breeding Facility of Shemyakin & Ovchinnikov Institute of Bioorganic Chemistry, Puschino, Moscow Region, Russia, and housed under specific pathogen free conditions on 12 h light /dark cycle at room temperature. All animal procedures were approved by the Scientific Council of the Engelhardt Institute of Molecular Biology.
Design, Expression, and Purification of MYSTI and STI Recombinant Antibodies. MYSTI and STI were generated using standard molecular cloning methods, expressed in E. coli and purified by immobilized metal ion affinity chromatography. Detailed procedures are described in SI Materials and Methods. Calculated molecular masses for MYSTI-1, STI-1, MYSTI-2, and STI-2 were 45, 42, 35, and 36 kDa; pIs were 6.8, 6.2, 8.6, and 8.1, respectively. Average yield was around 1 mg/L for MYSTI-1/STI-1 and around 50 mg/L for MYSTI-2/STI-2. All proteins were stable in solution at 4°C for at least 1 mo.
hTNF Interaction Assay by SPR. SPR experiments were performed using the ProteOn XPR36 system (Bio-Rad). MYSTI-1 and STI-1 were immobilized on a sensor chip by amine coupling, and then serial dilutions of hTNF were injected as analyte. MYSTI-2 was applied as analyte over immobilized hTNF. Further details can be found in SI Materials and Methods.
Cytotoxic Assay. Activity of MYSTI and STI in inhibiting TNF-mediated cytotoxicity was analyzed on L929 cell line. Detailed procedures are described in SI Materials and Methods.
Flow Cytometry Analysis. Peritoneal cavity cells and bone-marrow-derived macrophages from C57BL/6 mice were incubated with MYSTI or STI or culture media, then with or without recombinant hTNF, and stained for F4/80, for CD11b, and for either bound recombinant antibodies or hTNF. Samples were analyzed on FACSAria (BD Biosciences) or Guava EasyCyte 8HT system (Millipore), and data were analyzed using FlowJo (Treestar Inc.). Details of the experimental procedures and used antibodies can be found in SI Materials and Methods.
Analysis of Sequestration of hTNF on Macrophage Surface. Bone-marrowderived macrophages from TNF humanized mice (26) or peritoneal cavity cells enriched for macrophages were incubated with or without MYSTI or STI or anti-TNF V H H, washed, and stimulated with LPS. hTNF concentration in supernatants was determined by ELISA or by cytotoxic assay. A detailed description of the experimental design and procedures is provided in SI Materials and Methods.
LPS/D-Galactosamine-Induced Acute Hepatotoxicity Model. TNF humanized mice were maintained in a specific pathogen-free (SPF) facility. All animal experiments were performed in accordance with local ethical guidelines. Mice received 300, 750, and 1,500 U/g (activity was measured in cytotoxic assay) of either MYSTI-1 or STI-1 or vehicle buffer followed 30 min later by an otherwise lethal dose of LPS/D-Gal. In a separate set of experiments mice received 130 U/g of either MYSTI-2 or STI-2 or vehicle buffer and LPS/D-Gal injection 30 min later. Kaplan-Meier survival curves were plotted and pairwise statistical comparison of MYSTI and STI was performed for each concentration.
LPS Stimulation. TNF humanized mice received 25 μg of MYSTI-2 or STI-2 or vehicle buffer followed 30 min later by 10 μg of LPS. One hour later, peritoneal cavity cells and blood sera were collected. Cells were stained for surface MYSTI and analyzed by flow cytometry, and levels of hTNF in sera were measured by ELISA.
Statistical Analyses. Differences in Kaplan-Meier survival curves were analyzed by the log-rank (Mantel-Cox) test; other statistical comparisons were conducted using an unpaired two-tailed (Student's) t test. All statistical analyses were done using Prism software (GraphPad). Differences were considered significant when P values were <0.05.
